70
Participants
Start Date
November 30, 2024
Primary Completion Date
June 15, 2025
Study Completion Date
June 25, 2025
L-thyroxine
"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
Placebo Oral Tablet
patients will receive placebo oral tablet
Faculty of Medicine ,Ain Shams University, Cairo
Ain Shams University
OTHER